Listened to the presentation yesterday.. CEO brings up many valid reason as to why ZYNE treatment will be effective.. Time line for data was laid out.. They are targeting a niche market and not in direct competition with GWPH.. Looking to broaden their patents after phase 1 data is complete.. They will have enough money to get thru all their phase 2 trails.. Overall, positive takeaways from this presentation.. Trading slightly below its IPO price of $14 shares seem significantly undervalued IMO !
Market Data 
Markets 
AI
